

- Takashi NR, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen G and Reed J(1998):**A single BIR domain of XIAP sufficient for inhibiting caspases.J Biol Chem;273:7787-7790.
- Tamm I, Wanf F , Sausville W, et al (1998):** IAP- family protein Survivin inhibits caspase activity and apoptosis induced by fas (CD95),bax,caspases and anticancer drugs.Cancer Res;10:37373-44.
- Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000):** Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:27–134.
- Taub J, Konard Y and Naber J.(2002):**High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic lymphoma.Blood;99:299-304.
- Taylor RM, Metcalfe JA, Thick J and Mak YF (1996):** Leukemia and lymphoma in ataxia telangiectasia .Blood; 87 :423-38 .
- Thompson CB (1995):** Apoptosis in the pathogenesis and treatment of disease.Science; 267: 1456-1462.
- Toedling Jl, Rhein P, Ratei R, Karawajew L and Spang R (2006):** Automated in-silico detection of cell populations in flow cytometry readouts and its application to leukemia disease monitoring. BMC Bioinformatics; 7: 282-288.
- Troeger A,Seiperman M, Escherich G,meisel R,Gudowius S,Mortiz T. Laws H. Hanenberg H. Goebel G, Janka-Scnaub GE, Mahotka C and Dillo D (2007):** Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Hematologica; 92:1043-1050.
- Tucci F and Arico M (2008):** Treatment of pediatric acute lymphoblastic leukemia. Haematologica; 93(8): 1124-, 1128.
-

- Tusuda H, Haug RW and Takatsuki K (1993):** Interleukin-2 prevent programmed cell death in adult T-cell leukemia. *Cells JPnJ cancer Res*; 384:431
- Van Dijk MA, Voorhoeve PM, Murre C (1998):** Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia. *Proc Natl Acad Sci USA* 90. (13): 6061-6065.
- Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit a, Harris NL, Le Beau MM, Lindberg EH, Tefferi A and Bloomfield CD (2009):** the 2008 Revision of the WHO Classification of Myeloid Neoplasm and Acute leukemia: Rationale and Important Changes. *Blood* 209262 online 1st edition paper, April 8, 2009.
- Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al (1999):** Analysis of human transcriptomes. *Nat Genet*:23:387-8.
- Veredecia MA, Huang H, Dutil E, Kaiser DA, Hunter T and Noel JP (2000):** Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. *Nat Struct BioI* 7:7602-608.
- Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL (2000):** Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to an antagonizing IAP proteins. *Cell* **102**:43–53.
- Vousden KH and Lu X (2002):** Live or let die: The cells response to p53. *Nat Rev Cancer*, 2: 594-297.
- Wetzlar M (2000):** Cytogenetics in adult acute lymphoblastic leukemia. *Hematol Oncol Clin North Am*; 14 (6): 1237-1240.
-

- Wickermasinghe RG and Hoffbrand AV (2000):** The molecular basis of leukemia and lymphoma. In: Molecular Haematology. Edited by; Provan D and Gribber J, 1st. Blackwell Science, p.25-29.
- Williams GT, Nordan H and Ieshman F (1998):** Haemopoietic growth factors promote cell survival by suppressing apoptosis. Nature; 343:76.
- Wheless JR (1991):** Flow cytometry instrumentation and data analysis: 17-34
- Whitlock JA and Gaynon PS. (2004):** Acute Lymphoblastic Leukemia in Children Wintrobe's Clinical Hematology, 11th Ed Greer JP., Foerster J., Lukens JN. (eds) Lippincott Williams and Wilkins: 2143-2149.
- Wood JCs (1993):** Clinical flow cytometry instrumentation. Clinical flow cytometry, principles and application 71-92.
- Woolfrey A E, Anasetti C, Storer B, Doney K, Milner LA Sievers EL, Carpenter P, Paul M, Effie P, Frederick R A, John A Hansen, and Sanders J E (2002):** Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood; 99(6): 2002-2008.
- Wyllie All, Bellamy CO, Bubb VJ, Clarke AR, Corbet S and Curtis L (1999):** Apoptosis and carcinogenesis. Br J Cancer; 80(suppl1): 34-37.
- Xie Y, Davies SM, Xiang Yet al. (2003):** Trend in leukemia incidence and survival in the united states (1973-1998). Cancer; 97(9): 2229-35.
- Xichun Liu, Ruijuan Gao , Yan Dong, Lifang Gao, Yanying Zhao, Lijuan Zhao, Xuejian Zhao and Haitao Zhang (2010):**
-

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition, *BMC Cancer*;10:418-425.

Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S(2001):Survivin, bcl-2, and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas.*Int J Oncol* 19:537–542.

Zhou M,Gu L, Li F,ZhuY,Woods WG and findley HW(2002):DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. *J pharmacol Exp the* 303:124-131.

Zhongguo, Dang Dai, Er Ke andZa Zhi. (2006): Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy. *Ann Hematol*

Ziegler D, Pozza L, Waters K, and Marshall G (2005): Advances in childhood leukemia: successful clinical trials research leads to individualized therapy. *MJA*; 182 (2): 78.

Zwicker J, Lucibello FC, Wolfrain LA (1995): Cell cycle regulation of the cyclin A, cdc25C, and cdc2 genes is based on a common mechanism of transcriptional repression. *EMBO J* 14:4514–4522.